Company intelligence / Profile preview

Hephai

Paris / Orsay / Lyon, Île-de-France, Franceheph.ai ↗

Ownership: Private
Development stage: Other

Overview

Hephaistos has developed a new generation of detoxified and augmented TLR4 activators that have shown promising preclinical results in both liquid and solid refractory cancers. Their lead candidate, HEPHA-440, has orphan drug designation for osteosarcoma and is expected to enter clinical trials by 2027. The technology aims to turn immunologically "cold" tumors into "hot" ones, improving response rates in hard-to-treat cancers. Significant non-dilutive funding and seed investment have been secured to advance toward clinical development.

Therapeutic areas: Oncology
Modalities: Small molecule (engineered immune sensor modulators, specifically TLR4 activators)
Industry: Biotech

Partnerships

Collaborations with prestigious clinical centers in France as part of RHU grant/France2030 program

Beyond the preview

Go deeper on Hephai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hephai.

Explore the full profile